Phreesia, Inc. (PHR)
| Market Cap | 583.50M -60.0% |
| Revenue (ttm) | 495.59M +14.1% |
| Net Income | 9.18M |
| EPS | 0.15 |
| Shares Out | 61.81M |
| PE Ratio | 61.93 |
| Forward PE | 18.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,034,887 |
| Open | 9.11 |
| Previous Close | 9.15 |
| Day's Range | 9.02 - 9.44 |
| 52-Week Range | 7.77 - 32.76 |
| Beta | 0.88 |
| Analysts | Buy |
| Price Target | 13.94 (+47.67%) |
| Earnings Date | May 27, 2026 |
About PHR
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for PHR stock is "Buy." The 12-month stock price target is $13.94, which is an increase of 47.67% from the latest price.
News
PHR Stockholders Have Rights – If You Lost Money Investing in Phreesia, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO--(BUSINESS WIRE)---- $PHR #Inc--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Phreesia, Inc. (NYSE: PHR) commo...
Phreesia downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler downgraded Phreesia (PHR) to Neutral from Overweight with a price target of $12, down from $23.
Phreesia downgraded to Neutral at Piper on lack of growth visibility
Piper Sandler analyst Jessica Tassan downgraded Phreesia (PHR) to Neutral from Overweight with a price target of $12, down from $23. Phreesia is cutting costs to find profitability, but without…
Phreesia price target lowered to $16 from $22 at Canaccord
Canaccord lowered the firm’s price target on Phreesia (PHR) to $16 from $22 and keeps a Buy rating on the shares. The firm said Phreesia beat consensus revenue and adj-EBITDA…
Phreesia price target raised to $12 from $10 at Citi
Citi raised the firm’s price target on Phreesia (PHR) to $12 from $10 and keeps a Neutral rating on the shares. The company’s fiscal Q1 report came in better than…
Phreesia affirms FY27 revenue view of $510M-$520M, consensus $515.7M
The company states: “We are maintaining our revenue outlook for fiscal 2027. We expect revenue to be in the range of $510 million to $520 million. As we noted last…
Phreesia up 12% at $10.21 after Q1 results, affirmed guidance
16:28 EDT Phreesia (PHR) up 12% at $10.21 after Q1 results, affirmed guidance
Phreesia Earnings Call Transcript: Q1 2027
Revenue grew 13% year-over-year to $130.9 million, driven by payment and network solutions, with net income reaching $3 million and Adjusted EBITDA margin at 23%. Fiscal 2027 guidance is unchanged, with continued focus on AccessOne integration, operational efficiency, and new product momentum.
Phreesia Earnings release: Q1 2027
Phreesia released its Q1 2027 earnings on May 27, 2026, summarizing the period's financial results.
Phreesia Slides: Q1 2027
Phreesia has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on May 27, 2026.
Phreesia Shareholder letter: Q1 2027
Phreesia has published a letter to shareholders covering Q1 2027, which was released on May 27, 2026.
Phreesia Quarterly report: Q1 2027
Phreesia has published its Q1 2027 quarterly earnings report on May 27, 2026.
Phreesia reports Q1 adjusted EBITDA $30.5M vs. $20.8M last year
Reports Q1 revenue $130.9M, consensus $130.1M. Average number of healthcare services clients was 4,708 in the quarter, up 7% year-over-year. “Phreesia (PHR) had a solid first quarter to build on…
Phreesia Announces First Quarter Fiscal 2027 Results
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal first quarter ended April 30, 2026. “Phr...
REMINDER: Phreesia, Inc. Investors With Significant Losses Must Act By July 13, 2026
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Phreesia, Inc. (“Phreesia” or the “Company”) (NYSE:PHR) investors of the July 13, 2026 deadline to seek the role of lead plaintif...
Phreesia downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Stan Berenshteyn downgraded Phreesia (PHR) to Equal Weight from Overweight with a price target of $9, down from $15. The firm says its channel checks and Phreesia’s…
Phreesia downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Phreesia (PHR) to Equal Weight from Overweight with a $10 price target
Barclays downgrades Phreesia on slowing industry growth
Barclays analyst Glen Santangelo downgraded Phreesia (PHR) to Equal Weight from Overweight with a price target of $10, down from $24. Growth in the digital advertising space is slowing while…
Phreesia Proxy statement: Proxy filing
Phreesia filed a proxy statement on May 14, 2026, providing details for shareholder voting and corporate governance matters.
Phreesia Proxy statement: Proxy filing
Phreesia filed a proxy statement on May 14, 2026, providing details for shareholder voting and corporate governance matters.
Phreesia Sets Release Date for Fiscal First Quarter 2027 Results
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia will release its fiscal first quarter 2027 financial results after the close of market trading on Wednesday, May 27, 2026.
Phreesia Named to Becker's Hospital Review's 2026 List of “Revenue Cycle Management Companies to Know”
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, has been named to Becker's Hospital Review's 2026 list of “Revenue Cycle Management...
Phreesia price target lowered to $12 from $15 at KeyBanc
KeyBanc lowered the firm’s price target on Phreesia (PHR) to $12 from $15 and keeps an Overweight rating on the shares. Ahead of Q1 earnings, the firm believes the setup…
MediFind Becomes First Doctor Directory to Receive the Digital Medicine Society Seal
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--MediFind received the DiMe Seal, developed by the Digital Medicine Society, an independent nonprofit advancing the safe use of digital health.
Phreesia price target lowered to $15 from $25 at Wells Fargo
Wells Fargo lowered the firm’s price target on Phreesia (PHR) to $15 from $25 and keeps an Overweight rating on the shares. The company’s fiscal 2027 revenue outlook “decelerated sharply,”…